Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers developed prediction models that accurately predict erectile function after prostate cancer treatment based on pretreatment sexual function and patient characteristics. The models found that men who underwent certain treatments had a higher chance of regaining functional erections suitable for intercourse.
Research suggests that genetic variations in mRNA and microRNA play a critical role in prostate cancer disparities between African-American and white men. The findings could lead to more specialized treatment options for African-American patients.
Researchers found that high calcium intake increases prostate cancer risk among African-American men genetically predisposed to poor calcium absorption. This study provides insight into the link between diet and disease, suggesting personalized prevention strategies may be possible in the future.
A study by USC researchers suggests that high dietary intake of calcium causes prostate cancer among African-American men genetically good at absorbing the mineral. Men with poor calcium absorption were less likely to develop advanced prostate cancer.
Researchers aim to determine optimal Vitamin C dosing schedule and test therapy in septic patients to moderate organ dysfunction and improve outcomes. A potential new treatment for sepsis may be on the horizon thanks to a significant grant.
A team of researchers has identified five genetic variants that play a key role in the progression and mortality of prostate cancer. The discovery could lead to the development of a simple blood test to determine which patients need aggressive treatment versus conservative care.
A new urine-based test has been found to be more accurate than traditional prostate cancer screening methods, detecting the disease in 100% of cases while minimizing false positives. The PSA/SIA assay works by analyzing changes in PSA protein structure associated with cancer.
Researchers found that PHLPP1 and PTEN tumor suppressor genes work together to prevent lethal prostate cancer. The study suggests that monitoring gene transcription activity could predict patient outcomes and identify best candidates for clinical trials.
Researchers at Lund University have developed a new treatment option for advanced prostate cancer by targeting cancer stem cells with a STAT3-inhibitor. The study found that galiellalactone, a natural compound, has inhibitory effects on the growth of prostate cancer cells and prevents tumour growth and spreading.
Researchers at Beth Israel Deaconess Medical Center are receiving $1 million each from the Prostate Cancer Foundation to develop a vaccine that boosts patients' immune systems against prostate cancer. The goal of this treatment is to directly attack prostate-cancer cells and potentially be less expensive and more easily disseminated.
Researchers discovered a DNA biomarker, GSTP1, in bodily fluids that can complement the PSA test to increase prostate cancer diagnosis accuracy. The new blood test may reduce unnecessary biopsies and provide physicians with reassurance about biopsy recommendations.
A new urine test can help identify men at high risk of clinically significant prostate cancer, potentially delaying or avoiding needle biopsies. The test supplements an elevated PSA screening result and combines genetic markers to predict cancer presence.
Researchers have identified a new hormonal pathway driving advanced prostate cancer, which can be targeted by drugs. This discovery will help develop accurate biomarkers and improve treatment outcomes for resistant tumors.
A new study published in the New England Journal of Medicine found that combining short-term hormone therapy (ADT) with radiation therapy significantly improves overall survival rates for men with intermediate-risk prostate cancer. The treatment also resulted in a 10% reduction in disease-specific deaths among high-risk patients.
Scientists have developed a tiny fiber-optic biosensor to detect elevated PSA levels in cases of breast cancer. The biosensor's sensitivity and specificity are comparable to those found in current screening methods for breast cancer.
Researchers identified seven new DNA variants associated with increased prostate cancer risk, accounting for 25% of familial cancer risk. The study, conducted by an international consortium, used genome-wide association studies to identify genetic variants linked to the disease.
A recent study published in BJUI found that homosexual men taking bicalutamide for prostate cancer reported significant reductions in all aspects of their sexual functioning and satisfaction, ranging from 23% to 54%. In contrast, heterosexual men reported fewer problems and were more satisfied with intercourse.
A study found that men diagnosed with prostate cancer who are also smokers have an increased risk of dying from prostate cancer, as well as all-cause and cardiovascular disease mortality. Smoking cessation after diagnosis did not significantly impact mortality risks compared to never-smokers.
A new study from Harvard School of Public Health and University of California, San Francisco, found that men with prostate cancer who smoke are at higher risk of disease recurrence and mortality. Smoking was also associated with more aggressive disease at diagnosis.
Researchers found that prostate cancer can adapt to hormone therapy by activating a survival cell signaling pathway, making it more effective. The study's findings suggest that targeting both the androgen receptor and PI3K pathways may be necessary to effectively treat these cancers.
Scientists at Oregon State University have confirmed the safety and cancer-targeting ability of sulforaphane in a new study. Sulforaphane selectively kills cancer cells while leaving healthy prostate cells untouched, suggesting it could be used for cancer prevention and treatment.
A multi-site study has shown that the new drug Cabozantinib is effective in treating prostate cancer that has spread to the bone, with three-quarters of patients experiencing partial or complete tumor shrinkage. Additionally, patients showed significant improvements in bone pain and reduced need for narcotic use.
A prospective study found that smoking significantly increases a woman's risk for peripheral artery disease (PAD), which can cause pain and discomfort. The study also suggests that smoking cessation reduces the risk, but even after 20 years of abstention, the risk remains elevated.
A new targeted therapy, G-1, has been shown to halt the growth of tumors in animals with advanced prostate cancer resistant to hormone therapy. The treatment works by targeting and activating protein GPR30, which sensitizes tumor cells to its inhibiting effects.
Men with prostate cancer treated with hormone deprivation therapy may be at increased risk of developing diabetes or metabolic syndrome. According to the study, men in the ADT group had a twofold increased probability of having diabetes compared to those who did not receive hormonal therapy.
A multicenter clinical trial found stereotactic body radiation therapy (SBRT) to be an effective treatment option for patients with localized prostate cancer, delivering results in just five 30-minute sessions. The study's findings suggest that higher doses of radiation are safe and can lead to improved outcomes.
Researchers found that itraconazole can delay the progression of prostate cancer and reduce PSA levels, with 48.4% of patients experiencing stable or declining PSA after high-dose treatment. The antifungal also disrupted a key cancer-initiating biological pathway called Hedgehog.
A new experimental vaccine made from frozen immune cells has shown promise in extending the survival of metastatic prostate cancer patients. The vaccine, APC8015F, was found to increase median survival by approximately 10 months compared to those not treated with it.
A new study shows that abiraterone acetate, a life-extending pill for advanced prostate cancer, prolongs survival by about four months compared to placebo. The medication also reduces PSA blood levels in patients with the disease.
A recent study found that men who walk briskly after diagnosis have a 57% lower rate of progression of disease than those who walk at an easy pace. Brisk walking can delay or even prevent progression of prostate cancer.
A study of 1,455 U.S. men with early-stage prostate cancer found that brisk walking lowers the risk of prostate cancer progression by nearly 60%. Regular physical activity can improve prognosis, and walking must be brisk for benefits to occur.
A new study by American Cancer Society researchers found that long-term regular acetaminophen use was associated with a 38% lower risk of prostate cancer. The study suggests that acetaminophen may provide biological clues about prostate cancer development, warranting further research.
A genome-wide association study found a novel risk variant on chromosome 17q21 that is common in African American men but rare in other populations. This discovery builds on previous research identifying a risk region on chromosome 8q24, suggesting a genetic contribution to racial disparities in prostate cancer risk.
A new study from the University of Michigan Comprehensive Cancer Center finds that half of prostate cancers have a genetic anomaly making them responsive to PARP inhibitors. These drugs are being tested in breast cancer patients and show promise in shrinking tumors and blocking cancer spread.
A new study shows that nearly 70% of men with rising PSA levels and subsequent normal biopsies were eventually diagnosed with prostate cancer. Rising PSA velocity over several years should prompt clinicians to follow patients more closely, even with negative biopsy results.
New studies released by ASCO highlight advances in cervical cancer screening, ovarian cancer detection, and prostate cancer risk prediction. The studies also explore genetic biomarkers for chemotherapy-induced neuropathy and potential treatments for relapsed ovarian cancer.
A large-scale study found that men who drink coffee regularly have a lower risk of developing lethal prostate cancer. The study, led by Harvard School of Public Health researchers, also showed that decaf and regular coffee both reduced the risk, with even moderate consumption offering significant protection.
A new test measuring multiple parameters including PSA and six antibodies found in the blood of men with prostate cancer is more sensitive and specific than the conventional PSA test. The A+PSA assay reduces false-positives and shows great potential to improve prostate cancer diagnosis.
Men who are overweight or obese face a three-fold increased risk of cancer progression and more than a three-fold increased risk of metastases compared to normal-weight men. Obesity is linked to poorer outcomes in prostate cancer patients, regardless of treatment.
Researchers at Mayo Clinic found that patients diagnosed with advanced prostate cancer can enjoy long-term survival and a significant cancer-free interval. The study showed an 80% survival rate for patients with locally advanced prostate cancer at 20 years after surgery.
A new technology fusion of MRI with real-time 3D ultrasound improves targeted biopsy accuracy for prostate cancer diagnosis. The system identifies suspicious areas in the prostate and provides a roadmap for biopsy needle guidance, increasing cancer detection rates by five times compared to conventional biopsies.
Researchers combine Sabutoclax with viral gene therapy to prevent tumor growth in prostate-cancer-prone mice, offering a novel approach to treating advanced prostate cancer. The study's findings suggest that this combination therapy could be effective in other cancers and pave the way for personalized medicine.
Researchers find increased MAN2C1 levels enhance prostate cancer recurrence and metastasis, highlighting a potential target for blocking tumor progression. The study could lead to the development of new treatments for patients with advanced prostate cancer.
Scientists selectively sensitized prostate cancer cells to radiation therapy by knocking down a key protein repair gene. The approach shows promise for treating locally advanced prostate cancer, reducing disease recurrence.
A new biomarker for diagnosing prostate cancer has been found to be more reliable than current methods, reducing false positives and unnecessary operations. The study, published in PNAS, uses a unique test that detects elevated levels of prostasomes in blood, which are released by cancer cells into the surrounding tissue.
A Swedish research team found that surgery significantly reduces prostate cancer mortality risk, even among men with low-risk tumours. The study followed 347 patients and found that surgical patients had a lower risk of dying from prostate cancer than those who underwent watchful waiting.
A recent study published at the American Radium Society Annual Meeting found that aspirin use lowers the risk of cancer recurrence in prostate cancer patients who have received radiotherapy. After 10 years, men taking aspirin had a 31% lower rate of biochemical failure compared to non-aspirin users.
Researchers found that tissue spacers significantly reduced the rectal dose administered to patients receiving radiation therapy for prostate cancer. This led to minimal damage to the rectum, enabling radiation oncologists to increase treatment doses without concern.
Researchers at Georgetown University Medical Center report that a drug developed to treat Ewing's Sarcoma may also prevent human prostate cancer from spreading. The agent, YK-4 279, was found to inhibit functions of proteins responsible for aggressive cell behavior in prostate cancer cells.
Scripps Research and Moffitt Cancer Center collaborate on a $2.1 million grant to understand the origins of prostate cancer and develop novel treatments. The study aims to define how B cells control the spread of hormone-refractory cancer, potentially leading to effective treatments.
A nationwide study found that men with high levels of omega-3 fatty acids in their blood have a two-and-a-half times higher risk of developing aggressive prostate cancer. In contrast, those with high levels of trans-fatty acids had a 50% lower risk of high-grade prostate cancer.
A new study published in The Journal of Urology found that testosterone therapy does not cause rapid growth of prostate cancer in men with untreated or low-risk prostate cancer. Testosterone treatment was associated with improved symptoms and quality of life, without increasing the risk of cancer progression.
Thomas Jefferson University researchers show intensity-modulated radiotherapy (IMRT) delivers higher doses to the prostate bed while sparing surrounding tissue, leading to improved PSA levels and reduced side effects. The study fills a gap in documentation of this technique's benefits for post-operative patients.
A large-scale study of 769 men with low-grade prostate cancer found that closely monitoring the disease without immediate treatment does not raise the risk of death. Men who undergo active surveillance are less likely to need subsequent surgery or radiation if their cancer progression is carefully monitored.
A new PSA test has been shown to detect aggressive prostate cancer more accurately than current tests and reduce unnecessary biopsies. The Pro-PSA test uses a specific PSA subform called (-2) Pro-PSA and can be analyzed with a mathematical formula to provide an overall Prostate Health Index.
Researchers at Fox Chase Cancer Center have discovered two novel genetic markers associated with earlier time to prostate cancer diagnosis among African American men. Genetic variations in miRNA binding sites, particularly in genes IL-16 and IL-18, were found to increase the risk of early diagnosis.
U-M scientists identified a genetic anomaly in the KRAS gene, known for its role in numerous cancers, that may promote tumor progression in a rare subset of prostate cancers. This finding suggests different subtypes of prostate cancer will need targeted treatment strategies.
Researchers have identified an oncogenic gene fusion of KRAS in a metastatic prostate cancer cell line, shedding light on the genetic characteristics of this disease. This finding may enable better prognostic information to separate slow-growing tumors from aggressive ones, ultimately improving treatment strategies.
Researchers found that men using digoxin had a 24% lower risk of prostate cancer. The study also identified other approved drugs with anti-prostate cancer properties, paving the way for further research and potential new treatments.
A multidisciplinary team identified digoxin as a possible therapy for prostate cancer through drug repositioning. Regular digoxin use reduced the risk of prostate cancer by 24% and 46% for long-term users, respectively.